万邦德公告，全资子公司万邦德制药集团浙江医药销售有限公司获得西班牙Farmalider,S.A.的枸橼酸西 地那非口服混悬液在中国大陆市场10年的独家进口权和独家销售权。近日，万邦德销售公司收到授权方 礼易集团的通知，获悉西地那非口服混悬液已取得国家药品监督管理局核准签发的《药品注册证书》。 枸橼酸西地那非口服混悬液是一种对环磷酸鸟苷特异的5型磷酸二酯酶选择性抑制剂，临床用于治疗男 性勃起功能障碍。 ...

Core Viewpoint - The company is advancing the development of WP103, an innovative drug targeting Hypoxic-Ischemic Encephalopathy (HIE) in newborns, which currently has no approved treatments globally [1] Group 1: Disease Significance and Market Potential - HIE is a serious neonatal brain injury caused by lack of oxygen and reduced blood flow, leading to high mortality rates and long-term neurological issues such as cerebral palsy and epilepsy, imposing a heavy burden on families and society [1] - The market for HIE treatments is vast, with hundreds of thousands of infants affected annually, and the market capacity is expected to reach $10 billion [1] Group 2: Drug Development Progress - WP103 has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA, indicating its innovative value and potential for 7 years of market exclusivity, priority review for new drug applications, and exemption from registration fees [1] - Recent large animal efficacy studies have shown WP103's promising therapeutic effects on key indicators, improving behavioral, neurological scores, and brain tissue pathology [1] - The company plans to communicate with the FDA to advance clinical research for HIE following the completion of preclinical studies [1] Group 3: Company Strategy and Expertise - The company has focused on HIE as a breakthrough area due to the lack of available treatments and urgent clinical needs, supported by a dedicated R&D team of approximately 120 members [1] - The company has established high-end platforms, including a postdoctoral workstation and an academician workstation, and has closely collaborated with the FDA to design non-clinical studies, which has been crucial for the rapid advancement of the project [1]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced significant fluctuations, with a year-to-date increase of 107.62% but a recent decline of 9.25% over the last five trading days [1] - As of November 19, Wanbangde's stock price was reported at 13.35 yuan per share, with a total market capitalization of 8.166 billion yuan [1] - The company has seen a net inflow of main funds amounting to 503,000 yuan, with large orders showing a mixed buying and selling trend [1] Group 2 - Wanbangde Medical Holdings Group Co., Ltd. was established on March 31, 1999, and listed on November 20, 2006, with its main business involving the production and sales of aluminum processing products and medical devices [2] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average circulating shares per person increased by 48.70% to 20,944 shares [2] Group 3 - Wanbangde has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002082 证券简称：万邦德 公告编号：2025-063 万邦德医药控股集团股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、会议召开时间： 1）现场会议时间：2025年11月17日下午14:00。 2）网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为2025年11月17日9:15-9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网系统进行投票的具体时间为2025年11月17日9:15至 15:00的任意时间。 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简称"公司"）董事会 4、会议主持人：董事刘同科先生。 5、会议召开方式：本次会议采取现场投票表决和网络投票表决相结合的方式召开。 会议的召集 ...

Core Viewpoint - The stock of Shuoshi Biotechnology fell nearly 15% in the afternoon, with several other companies including Anglikang, Wanbangde, Kanglong Huacheng, Meidixi, Haoyuan Pharmaceutical, Jindike, and Jinshiyao also experiencing declines of over 5% [1] Company Performance - Shuoshi Biotechnology's stock decline of nearly 15% indicates significant market volatility [1] - Other companies in the sector, such as Anglikang and Wanbangde, also faced notable stock price drops, suggesting a broader trend affecting multiple firms [1] - The overall performance of the biotechnology sector appears to be under pressure, as indicated by the collective decline of several key players [1]

每经头条（nbdtoutiao）——展望"十五五" | 专访尹艳林：让有钱且愿消费的人顺利消费；个税起征点可 提高，最高边际税率可下调，让有关群体少缴税、多收入 （记者 张明双） 2025年1至6月份，万邦德的营业收入构成为：专用设备制造及服务占比41.63%，医药制造占比 38.76%，其他行业占比12.31%，医药流通占比7.3%。 截至发稿，万邦德市值为83亿元。 每经AI快讯，万邦德（SZ 002082，收盘价：13.61元）11月17日晚间发布公告称，公司第九届第十九次 董事会会议于2025年11月17日在公司行政楼会议室以现场结合通讯方式召开。会议审议了《关于确认董 事会审计委员会成员及召集人的议案》等文件。 ...

关 于 万邦德医药控股集团股份有限公司 2025 年第三次临时股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 国浩律师（杭州）事务所 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二五年十一月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 万邦德医药控股集团股份有限公司 2025 年第三次临时股东大会 法律意见书 致：万邦德医药控股集团股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受万邦德医药控股集团股 份有限公司（以下简称"公司"）委托，指派律师出席公司 2025 年第三次临时股 东大会（ ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 证券代码：002082 证券简称：万邦德 公告编号：2025-063 万邦德医药控股集团股份有限公司 2025年第三次临时股东大会决议公告 一、会议召开情况 1、会议召开时间： 1）现场会议时间：2025年11月17日下午14:00。 2）网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为2025 年11月17日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网 系统进行投票的具体时间为2025年11月17日9:15至15:00的任意时间。 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政 楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简称"公司"） 董事会 4、会议主持人：董事刘同科先生。 5、会议召开方式：本次会议采取现场投票表决和网络投票表决相结合的方 式召开。 会议的召集、召开及表决程序符合《公司法》等相关法律法规 ...

第九届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届董事会第十 九次会议通知于 2025 年 11 月 17 日以邮件、微信等方式发出，召集人已对本次会 议作出说明，经全体董事书面同意豁免提前发出会议通知的时限要求，与会的各 位董事已知悉所审议事项相关的必要信息，会议于 2025 年 11 月 17 日在公司行政 楼会议室以现场结合通讯方式召开。本次会议由董事刘同科先生主持，会议应到 董事 9 人，实到董事 9 人，赵守明先生、庄惠女士、周岳江先生、李杨女士、屠 鹏飞先生以通讯方式出席会议并参与表决，公司高级管理人员列席会议。会议的 召集、召开及表决程序符合有关法律法规、规范性文件和《公司章程》等有关规 定。 证券代码：002082 证券简称：万邦德 公告编号：2025-064 万邦德医药控股集团股份有限公司 根据《公司法》和《公司章程》的最新规定，董事会同意选举公司赵守明先 生为代表公司执行事务的董事，并担任公司法定代表人，任期自本次董事会审议 通过 ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 1.47% on November 17, with Wanbangde leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Jiaying Pharmaceutical (002198) with a closing price of 8.43, up 10.05% and a trading volume of 390,200 shares [1] - Weikang Pharmaceutical (300878) closed at 29.62, up 6.85% with a trading volume of 97,100 shares [1] - Significant losers included: - Wanbangde (002082) closed at 13.61, down 6.91% with a trading volume of 186,000 shares [2] - Teyi Pharmaceutical (002728) closed at 14.17, down 6.84% with a trading volume of 1,277,300 shares [2] Capital Flow - The traditional medicine sector saw a net outflow of 1.639 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.444 billion yuan [2][3] - The main stocks with significant capital inflow included: - Jiaying Pharmaceutical with a net inflow of 62.818 million yuan, accounting for 19.12% of its trading volume [3] - Huasheng Technology (000790) with a net inflow of 20.121 million yuan, representing 11.37% of its trading volume [3]